Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates include BTI-320, a non-systemic, carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients; and IPOXYN, a carbohydrate-based, injectable drug to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. The company also develops OxyFex, an oxygen delivery agent for ischemia and trauma for blood loss during surgery in veterinary medicine applications. In addition, it produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement to support healthy post-meal blood glucose. The company was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. Boston Therapeutics, Inc. was founded in 2009 and is headquartered in Lawrence, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone603-935-9799
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30,000.00
Profitability
Miscellaneous
Employees2
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Boston Therapeutics (OTCMKTS:BTHE) Frequently Asked Questions
What is Boston Therapeutics' stock symbol?
Boston Therapeutics trades on the OTCMKTS under the ticker symbol "BTHE."
How were Boston Therapeutics' earnings last quarter?
Boston Therapeutics Inc (OTCMKTS:BTHE) released its quarterly earnings results on Monday, May, 14th. The company reported ($0.03) earnings per share (EPS) for the quarter. The firm earned $0.01 million during the quarter. View Boston Therapeutics' Earnings History.
When is Boston Therapeutics' next earnings date?
Has Boston Therapeutics been receiving favorable news coverage?
Media coverage about BTHE stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Boston Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Boston Therapeutics.
Who are some of Boston Therapeutics' key competitors?
Some companies that are related to Boston Therapeutics include Midatech Pharma (MTP), Cotinga Pharmaceuticals (COTQF), Innovus Pharmaceuticals (INNVD), Nuvo Pharmaceuticals (NRIFF), International Stem Cell (ISCO), Auris Medical (EARS), MOTIF BIO PLC/S (MTFB), Immune Therapeutics (IMUN), Parnell Pharmaceuticals (PARNF), Ritter Pharmaceuticals (RTTR), Wize Pharma (WIZP), American Bio Medica (ABMC), Global Future City (FTCY), IntelliPharmaCeutics Intl (IPCIF) and ContraVir Pharmaceuticals (CTRV).
What other stocks do shareholders of Boston Therapeutics own?
Who are Boston Therapeutics' key executives?
Boston Therapeutics' management team includes the folowing people:
- Mr. Carl W. Rausch, CEO, CFO & Director (Age 70)
- Dr. Meng Hee Tan, Consulting Medical Director
How do I buy shares of Boston Therapeutics?
Shares of BTHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Boston Therapeutics' stock price today?
One share of BTHE stock can currently be purchased for approximately $0.01.
How big of a company is Boston Therapeutics?
What is Boston Therapeutics' official website?
How can I contact Boston Therapeutics?
Boston Therapeutics' mailing address is 354 MERRIMACK STREET #4, LAWRENCE MA, 01843. The company can be reached via phone at 603-935-9799 or via email at [email protected]
MarketBeat Community Rating for Boston Therapeutics (OTCMKTS BTHE)
MarketBeat's community ratings are surveys of what our community members think about Boston Therapeutics and other stocks. Vote "Outperform" if you believe BTHE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTHE will underperform the S&P 500 over the long term. You may vote once every thirty days.
